133040 - PPI: Reviewing treatment for gastro-oesophageal reflux disease - National Case Study
- : Online
This online interactive case study supports best practice use of proton pump inhibitors (PPIs) for managing GORD, specifically addressing the recommended use of PPIs, providing guidance on starting, stepping down and stopping treatment, as well as long-term risks.Relevance to General Practice
Gastro-oesophageal reflux is common, with 15-20% of Australians experiencing heartburn at least once a week. Gastro-oesophageal reflux disease (GORD) occurs when patients experience symptoms of reflux which are frequent (two or more episodes per week) or severe enough to significantly impair quality of life, and is managed primarily with lifestyle changes and medicines.
Current guidelines for GORD recommend starting treatment on a short-term standard-dose PPI (4-8 weeks), followed by regular review to step down to the lowest effective dose, or stop the medicine completely. However, evidence suggests most PPIs are being used long term, often unnecessarily and without appropriate indication.
While PPIs are generally considered safe, there is some emerging evidence of rare but serious adverse effects that also need to be considered.
This online interactive case study will address the management of GORD, specifically focusing on the appropriate use of PPIs.